At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 16 enrolled
Drug / intervention
Emicizumabdrug
Likely dose
Emicizumab 1 milligramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Center, Open-Label, Single Dose Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Emicizumab in Healthy Chinese Volunteers
In Brief
A Phase 1 clinical trial evaluating Emicizumab for Healthy Volunteers and Hemophilia A. Completed, enrolled 16 participants across 1 site.
Detailed Summary
This single-center, open-label study will evaluate the pharmacokinetics, safety, and tolerability of emicizumab following a single subcutaneous (SC) administration to healthy Chinese subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers, Hemophilia A
CountriesChina
Collaborators--
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedDec 2017
Enrollment StartMar 2018
Primary CompletionSep 2018
TodayJul 2026
First PostedDec 21, 2017
Enrollment StartMar 12, 2018
Primary CompletionSep 18, 2018
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 8.5 years ago
Interventions
Emicizumabdrug
Participants will receive a single 1 milligram per kilogram of body weight (mg/kg) subcutaneous dose of emicizumab on Day 1.